Solvay Pharma Inc. et al. v. Apotex Inc. et al., (2008) 323 F.T.R. 1 (FC)

This document cites

• Wyeth Canada et al. v. ratiopharm inc. et al., (2007) 310 F.T.R. 265 (FC)
• Ferring Inc. v. Canada (Minister of Health) et al., (2007) 370 N.R. 263 (FCA)
• Lundbeck (H.) A/S et al. v. Canada (Minister of Health) et al., 2003 FC 1145
• Abbott Laboratories et al. v. Canada (Attorney General) et al., 2007 FC 444
• Apotex Inc. et al. v. Canada (Minister of National Health and Welfare) et al., (1999) 252 N.R. 72 (FCA)



See all quotations

• Bristol-Myers Squibb Co. et al. v. Canada (Attorney General) et al., (2005) 334 N.R. 55 (SCC)
• Eli Lilly & Co. et al. v. Nu-Pharm Inc. et al., (1996) 199 N.R. 185 (FCA)
• AB Hassle et al. v. Canada (Minister of National Health and Welfare) et al., 2002 FCA 421
• Whirlpool Corp. et al. v. Camco Inc. et al., (2000) 263 N.R. 88 (SCC)
• Abbott Laboratories et al. v. Canada (Minister of Health) et al., (2007) 370 N.R. 109 (FCA)
• Ferring Inc. v. Canada (Minister of Health) et al., (2007) 310 F.T.R. 185 (FC)
• Aventis Pharma Inc. et al. v. Apotex Inc. et al., (2006) 354 N.R. 383 (FCA)
• Free World Trust v. Électro Santé Inc. et al., (2000) 263 N.R. 150 (SCC)
• Pfizer Canada Inc. et al. v. Apotex Inc. et al., 2005 FC 1421
• AB Hassle et al. v. Canada (Minister of National Health and Welfare) et al., (2001) 213 F.T.R. 161 (TD)
• Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al., (2005) 285 F.T.R. 1 (FC)
• Procter & Gamble Pharmaceuticals Canada Inc. et al. v. Canada (Minister of Health) et al., 2002 FCA 290
• Pfizer Canada Inc. v. Canada (Minister of Health) et al., (2006) 354 N.R. 294 (FCA)
• Sanofi-Aventis Canada Inc. et al. v. Novopharm Ltd. et al., (2007) 366 N.R. 231 (FCA)
• Wyeth Canada et al. v. ratiopharm inc. et al., 2007 FCA 264
• Dableh v. Ontario Hydro, (1996) 199 N.R. 57 (FCA)
• Solvay Pharma Inc. et al. v. Apotex Inc. et al., [2007] F.T.R. Uned. 579
• Abbott Laboratories Ltd. et al. v. Canada (Minister of Health) et al., 2006 FC 1411
• Sanofi-Aventis Canada Inc. v. Novopharm Ltd. et al., (2007) 364 N.R. 325 (FCA)
• Pfizer Can. Inc. v. Novopharm, 2005 FCA 270
• Abbott Laboratories Ltd. et al. v. Canada (Minister of Health) et al., 2007 FCA 251
• Aventis Pharma Inc. v. Apotex Inc. et al., 2006 FCA 64
• Hoffmann-La Roche Ltd. et al. v. Canada (Minister of National Health and Welfare) et al., (1996) 205 N.R. 331 (FCA)
• AB Hassle et al. v. Genpharm Inc. et al., (2003) 243 F.T.R. 6 (FC)
• AB Hassle et al. v. Apotex Inc. et al., (2003) 312 N.R. 288 (FCA)
• AstraZeneca AB et al. v. Apotex Inc. et al., (2004) 245 F.T.R. 196 (FC)
• AB Hassle et al. v. Apotex Inc. et al., (2002) 223 F.T.R. 43 (TD)
• AstraZeneca AB et al. v. Apotex Inc. et al., 2007 FC 688
• AstraZeneca Canada Inc. v. Canada (Minister of Health) et al., (2006) 354 N.R. 88 (SCC)
• Pfizer Canada Inc. v. Canada (Minister of Health) et al., (2006) 288 F.T.R. 235 (FC)